Topics

DCL05, an AI-guided degrader, eliminates the CLIP1-LTK fusion protein at 40 picomolar — clearing both kinase and scaffolding functions that standard inhibitors miss.

UK rationing data shows early-life sugar restriction halves liver and prostate cancer risk, lengthens telomeres by 2.2 years, and reshapes taste for life.

A custom treatment built from each patient's tumor mutations, given with an existing immunotherapy, met its main goals in a large late-stage study and relies on computational ranking of targets.

University of Chicago scientists rewired Bifidobacterium longum to pump SumIL-2 inside tumors, suppressing pancreatic cancer growth in mouse models.

Scientists designed CRISPR to self-destruct tumor cells carrying p53 mutations, a target no drug has ever reached. A Nature paper details the approach for ovarian, pancreatic, and lung cancers.

AI trained on Swedish registry data predicts melanoma risk five years ahead with 73% accuracy, enabling targeted screening of high‑risk groups and more efficient use of healthcare resources.

A scientist who is a cancer patient decided to cure herself with oncolytic viruses. She has now been cancer-free for four years.

New translational data demonstrate Pelareorep's ability to activate tumor-specific immune responses in KRAS-mutant pancreatic and breast cancers.

UCLA researchers discovered that creatine fuels the immune system's cancer-fighting command cells, opening a surprising new avenue for future immunotherapies.